These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312 [TBL] [Abstract][Full Text] [Related]
3. The disposition of carboplatin in ovarian cancer patients. Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of carboplatin after i.v. administration. Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135 [TBL] [Abstract][Full Text] [Related]
5. The disposition of carboplatin in the beagle dog. Gaver RC; George AM; Duncan GF; Morris AD; Deeb G; Faulkner HC; Farmen RH Cancer Chemother Pharmacol; 1988; 21(3):197-202. PubMed ID: 3282707 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial. van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966 [TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of carboplatin. van der Vijgh WJ Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899 [TBL] [Abstract][Full Text] [Related]
8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. el-Yazigi A; Amer M; Martin CR Pharm Res; 1989 Jun; 6(6):492-6. PubMed ID: 2668915 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial. Elferink F; van der Vijgh WJ; ten Bokkel Huinink WW; Vermorken JB; Klein I; Winograd B; Knobf MK; Simonetti G; Gall HE; McVie JG Br J Cancer; 1987 Oct; 56(4):479-83. PubMed ID: 3689665 [TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and dose optimisation of carboplatin. Duffull SB; Robinson BA Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days. Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of oxaliplatin: a critical review. Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of carboplatin after intraperitoneal administration. Elferink F; van der Vijgh WJ; Klein I; ten Bokkel Huinink WW; Dubbelman R; McVie JG Cancer Chemother Pharmacol; 1988; 21(1):57-60. PubMed ID: 3277734 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic properties of platinium derivatives]. Boisdron-Celle M; Lebouil A; Allain P; Gamelin E Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909 [TBL] [Abstract][Full Text] [Related]
20. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Siddik ZH; Newell DR; Boxall FE; Harrap KR Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]